Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?

Diabetes, Obesity and Metabolism

Volumn 20, Issue 12, 2018, Pages 2711-2723

  Raschi, Emanuel ^a   Poluzzi, Elisabetta ^a   Fadini, Gian Paolo ^b   Marchesini, Giulio ^a   De Ponti, Fabrizio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

cardiovascular outcome trials; CVD REAL; real world; safety; sodium glucose co transporter 2 inhibitors

Indexed keywords

CANAGLIFLOZIN; EMPAGLIFLOZIN; HEMOGLOBIN A1C; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ALBUMINURIA; ALL CAUSE MORTALITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; CLINICAL RESEARCH; DATA ANALYSIS; DIABETIC KETOACIDOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; TREATMENT RESPONSE; COHORT ANALYSIS; COMPLICATION; OBSERVATIONAL STUDY; RISK FACTOR; TREATMENT OUTCOME;

BENZHYDRYL COMPOUNDS; CANAGLIFLOZIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; OBSERVATIONAL STUDIES AS TOPIC; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME;

EID: 85052524323     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13468     Document Type: Review

References (76)

1. Goyat R, Rai P, Chang J, et al. Cardiovascular mortality of oral antidiabetic drugs approved before and after the 2008 US FDA guidance for industry: a systemic review and meta-analysis. Clin Drug Investig. 2018;38:491-501.
2. Sattar N, Petrie MC, Zinman B, Januzzi JL Jr. Novel diabetes drugs and the cardiovascular specialist. J Am Coll Cardiol. 2017;69:2646-2656.
3. Cefalu WT, Kaul S, Gerstein HC, et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a diabetes care Editors' expert forum. Diabetes Care. 2018;41:14-31.
4. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.
5. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657.
6. Makady A, de Boer A, Hillege H, et al. What is real-world data? A review of definitions based on literature and stakeholder interviews. Value Health. 2017;20:858-865.
7. Najafzadeh M, Gagne JJ, Schneeweiss S. Synergies from integrating randomized controlled trials and real-world data analyses. Clin Pharmacol Ther. 2017;102:914-916.
8. Chatterjee S, Davies MJ, Khunti K. What have we learnt from "real world" data, observational studies and meta-analyses. Diabetes Obes Metab. 2018;20(suppl 1):47-58.
9. Franklin JM, Schneeweiss S. When and how can real world data analyses substitute for randomized controlled trials? Clin Pharmacol Ther. 2017;102:924-933.
10. Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose Cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose Cotransporter-2 inhibitors). Circulation. 2017;136:249-259.
11. Birkeland KI, Jorgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017;5:709-717.
12. Persson F, Nystrom T, Jorgensen ME, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study. Diabetes Obes Metab. 2018;20:344-351.
13. Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol. 2018;71:2628-2639.
14. Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N. Cardiovascular outcomes and risks after initiation of a sodium glucose Cotransporter 2 inhibitor: results from the EASEL population-based cohort study (evidence for cardiovascular outcomes with sodium glucose Cotransporter 2 inhibitors in the real world). Circulation. 2018;137:1450-1459.
15. Patorno E, Goldfine AB, Schneeweiss S, et al. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ. 2018;360:119.
16. Toulis KA, Willis BH, Marshall T, et al. All-cause mortality in patients with diabetes under treatment with Dapagliflozin: a population-based, open-cohort study in the health improvement network database. J Clin Endocrinol Metab. 2017;102:1719-1725.
17. Nystrom T, Bodegard J, Nathanson D, et al. Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19:831-841.
18. Suissa S. Lower risk of death with SGLT2 inhibitors in observational studies: real or bias? Diabetes Care. 2018;41:6-10.
19. Nystrom T, Bodegard J, Nathanson D, et al. Comment on Suissa. Lower risk of death with SGLT2 inhibitors in observational studies: real or bias? Diabetes Care 2018;41:6-10. Diabetes Care. 2018;41:e104-e105.
20. Thuresson M, Cavender MA, Fu AZ, et al. Comment on Suissa. Lower risk of death with SGLT2 inhibitors in observational studies: real or bias? Diabetes Care 2018;41:6-10. Diabetes Care. 2018;41:e106-e108.
21. Suissa S. Response to comment on Suissa. Lower risk of death with SGLT2 inhibitors in observational studies: real or bias? Diabetes Care 2018;41:6-10. Diabetes Care. 2018;41:e109-e110.
22. Cavender MA, Norhammar A, Birkeland KI, et al. SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL. J Am Coll Cardiol. 2018;71:2497-2506.
23. Kosiborod M, Birkeland KI, Cavender MA, et al. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: results from the CVD-REAL study. Diabetes Obes Metab. 2018;20:1983-1987.
24. Ryan PB, Buse JB, Schuemie MJ, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab. 2018;20:2585-2597.
25. Rawson NSB, D'Arcy C. Healthcare databases for drug safety research: data validity assessment remains crucial. Drug Saf. 2018 [Epub ahead of print]. https://doi.org/10.1007/s40264-018-0673-z.
26. Wang SV, Schneeweiss S, Berger ML, et al. Reporting to improve reproducibility and facilitate validity assessment for healthcare database studies V1.0. Value Health. 2017;20:1009-1022.
27. Bate A. Guidance to reinforce the credibility of health care database studies and ensure their appropriate impact. Pharmacoepidemiol Drug Saf. 2017;26:1013-1017.
28. Berger ML, Sox H, Willke RJ, et al. Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017;26:1033-1039.
29. Roberto G, Leal I, Sattar N, et al. Identifying cases of type 2 diabetes in heterogeneous data sources: strategy from the EMIF project. PLoS One. 2016;11:e0160648.
30. Patorno E, Patrick AR, Garry EM, et al. Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations. Diabetologia. 2014;57:2237-2250.
31. Patorno E, Garry EM, Patrick AR, et al. Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a review. Drug Saf. 2015;38:295-310.
32. Grimes DA, Schulz KF. False alarms and pseudo-epidemics: the limitations of observational epidemiology. Obstet Gynecol. 2012;120:920-927.
33. Elze MC, Gregson J, Baber U, et al. Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies. J Am Coll Cardiol. 2017;69:345-357.
34. Wang SV, He M, Jin Y, et al. A review of the performance of different methods for propensity score matched subgroup analyses and a summary of their application in peer-reviewed research studies. Pharmacoepidemiol Drug Saf. 2017;26:1507-1512.
35. Prentice JC, Conlin PR, Gellad WF, Edelman D, Lee TA, Pizer SD. Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes. Value Health. 2014;17:854-862.
36. Patorno E, Gopalakrishnan C, Franklin JM, et al. Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records. Diabetes Obes Metab. 2018;20:974-984.
37. Fadini GP, Zatti G, Baldi I, et al. Use and effectiveness of dapagliflozin in routine clinical practice: an Italian multicentre retrospective study. Diabetes Obes Metab. 2018;20:1781-1786.
38. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S73-S85.
39. Li L, Li S, Deng K, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ. 2016;352:i610.
40. Fadini GP, Saragoni S, Russo P, et al. Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: results from the OsMed health-DB registry. Diabetes Obes Metab. 2017;19:1416-1424.
41. Scheen AJ. Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ Res. 2018;122:1439-1459.
42. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
43. Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium glucose Cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 2017;136:1643-1658.
44. Custodio JS Jr, Duraes AR, Abreu M, et al. SGLT2 inhibition and heart failure-current concepts. Heart Fail Rev. 2018;23:409-418.
45. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323-334.
46. Scheen AJ. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet. 2015;54:691-708.
47. Szalat A, Perlman A, Muszkat M, Khamaisi M, Abassi Z, Heyman SN. Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia. Drug Saf. 2018;41:239-252.
48. Perlman A, Heyman SN, Matok I, Stokar J, Muszkat M, Szalat A. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: analysis of the FDA adverse event report system database. Nutr Metab Cardiovasc Dis. 2017;27:1108-1113.
49. Desai M, Yavin Y, Balis D, et al. Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2017;19:897-900.
50. Raschi E, Parisotto M, Forcesi E, et al. Adverse events with sodium-glucose co-transporter-2 inhibitors: a global analysis of international spontaneous reporting systems. Nutr Metab Cardiovasc Dis. 2017;27:1098-1107.
51. Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19:348-355.
52. Filippas-Ntekouan S, Filippatos TD, Elisaf MS. SGLT2 inhibitors: are they safe? Postgrad Med. 2018;130:72-82.
53. Bonora BM, Avogaro A, Fadini GP. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: an updated review of the literature. Diabetes Obes Metab. 2018;20:25-33.
54. Monami M, Nreu B, Zannoni S, Lualdi C, Mannucci E. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: a meta-analysis of randomised controlled trials. Diabetes Res Clin Pract. 2017;130:53-60.
55. Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA adverse event reporting system. Diabetologia. 2017;60:1385-1389.
56. Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med. 2017;376:2300-2302.
57. Kim YG, Jeon JY, Han SJ, Kim DJ, Lee KW, Kim HJ. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: a nationwide population-based cohort study. Diabetes Obes Metab. 2018;20:1852-1858.
58. Mannucci E, Monami M. Bone fractures with sodium-glucose co-transporter-2 inhibitors: how real is the risk? Drug Saf. 2017;40:115-119.
59. Toulis KA, Bilezikian JP, Thomas GN, et al. Initiation of dapagliflozin and treatment-emergent fractures. Diabetes Obes Metab. 2018;20:1070-1074.
60. Yuan Z, DeFalco FJ, Ryan PB, et al. Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: a retrospective cohort study. Diabetes Obes Metab. 2018;20:582-589.
61. Fadini GP, Avogaro A. SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol. 2017;5:680-681.
62. Khouri C, Cracowski JL, Roustit M. SGLT-2 inhibitors and the risk of lower-limb amputation: is this a class effect? Diabetes Obes Metab. 2018;20:1531-1534.
63. Scheen AJ. Does lower limb amputation concern all SGLT2 inhibitors? Nat Rev Endocrinol. 2018;14:326-328.
64. Bonaca MP, Beckman JA. Sodium glucose cotransporter 2 inhibitors and amputation risk: achilles' heel or opportunity for discovery? Circulation. 2018;137:1460-1462.
65. Faillie JL. Pharmacological aspects of the safety of gliflozins. Pharmacol Res. 2017;118:71-81.
66. Fadini GP, Bonora BM, Mayur S, Rigato M, Avogaro A. Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2018;20:740-744.
67. Fadini GP, Sarangdhar M, Avogaro A. Pharmacovigilance evaluation of the association between DPP-4 inhibitors and heart failure: stimulated reporting and moderation by drug interactions. Diabetes Ther. 2018;9:851-861.
68. Ioannidis JP. The mass production of redundant, misleading, and conflicted systematic reviews and meta-analyses. Milbank Q. 2016;94:485-514.
69. Riaz IB, Khan MS, Riaz H, et al. Disorganized systematic reviews and meta-analyses: time to systematize the conduct and publication of these study overviews? Am J Med. 2016;129:339.e11-339.e18.
70. Packer M. Are meta-analyses a form of medical fake news? Thoughts about how they should contribute to medical science and practice. Circulation. 2017;136:2097-2099.
71. Raschi E, Poluzzi E, Salvo F, et al. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutr Metab Cardiovasc Dis. 2018;28:533-542.
72. Radholm K, Wu JH, Wong MG, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – a systematic review. Diabetes Res Clin Pract. 2018;140:118-128.
73. Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18:783-794.
74. Zheng SL, Roddick AJ, Ghar-Jaffar R, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and Dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA. 2018;319:1580-1591.
75. Salanti G, Del GC, Chaimani A, et al. Evaluating the quality of evidence from a network meta-analysis. PLoS One. 2014;9:e99682.
76. Riley RD, Jackson D, Salanti G, et al. Multivariate and network meta-analysis of multiple outcomes and multiple treatments: rationale, concepts, and examples. BMJ. 2017;358:j3932.